

**New Drug Development for Known and  
Emerging Viruses**

*Edited by*

*Helga Rübsamen-Schaeff and Helmut Buschmann*

**WILEY-VCH**

## Contents

<b>Preface</b>	<i>xv</i>
<b>In Memoriam: Farah Elawar</b>	<i>xvii</i>
<b>Introduction</b>	<i>xix</i>
<b>References</b>	<i>xx</i>
<b>1 HIV—Disease Overview, Targets for Therapy and Open Issues</b>	<b>1</b>
<i>Christoph Stephan</i>	
1.1 HIV—Disease Overview	1
1.2 Targets for Antiretroviral Therapy	2
1.3 Currently Open Issues in HIV/AIDS Research	10
References	10
<b>2 Curing Hepatitis C with Direct-Acting Antiviral Therapy</b>	<b>13</b>
<i>Michael J. Sofia</i>	
2.1 Introduction	13
2.2 Tools to Enable Drug Discovery	14
2.3 Drug Discovery Targets	15
2.4 NS5B Polymerase Inhibitors	15
2.4.1 Nucleoside and Nucleotide Inhibitors of NS5B Polymerase	15
2.4.2 Non-nucleoside NS5B Inhibitors	19
2.5 HCV NS3/4A Protease Inhibitors	22
2.5.1 HCV NS3/4A Protease Acyclic Reversible Inhibitors	25
2.5.2 HCV NS3/4A Protease Acyclic Covalent Binding Inhibitors	25
2.5.3 HCV NS3/4A Protease Macrocyclic Reversible Inhibitors	30
2.5.4 HCV NS3/4A Protease P2–P4 Macrocyclic Inhibitors	30
2.6 HCV NS5A Inhibitors	32
2.7 The Evolution of DAA Combination Therapies	35
2.8 Conclusion	41
Acknowledgment	41
References	41

<b>3</b>	<b>Antiviral Drugs Against Influenza Virus</b>	<b>59</b>
	<i>Oliver Planz</i>	
3.1	The Influenza Virus	59
3.2	The Pathogenesis of Influenza	60
3.3	Influenza Drugs and Targets	62
3.4	Adamantanes and Derivatives	63
3.5	Neuraminidase Inhibitors	64
3.5.1	Oseltamivir	65
3.5.2	Zanamivir	66
3.5.3	Peramivir	67
3.5.4	Laninamivir	69
3.5.5	Summary	70
3.6	Polymerase-Inhibitors	70
3.6.1	Baloxavir Marboxil (BAM)	70
3.6.2	Favipiravir	73
3.6.3	Pimodivir	75
3.6.4	Summary	76
3.7	Monoclonal Antibodies	76
3.7.1	MHAA4549A	77
3.7.2	MEDI8852	77
3.7.3	VIS410	78
3.7.4	Summary	78
3.8	Host-Targeting Candidates	79
3.8.1	DAS181	79
3.8.2	Nitazoxanide	80
3.8.3	LASAG	81
3.8.4	Summary	82
	References	82
<b>4</b>	<b>Respiratory Syncytial Virus Immunoreactivity, Vaccine Development, and Therapeutics</b>	<b>97</b>
	<i>Farah Elawar, Matthias Gotte, Nelson Lee, Rachel Fearn, and David J. Marchant</i>	
4.1	Introduction	97
4.1.1	The Burden of RSV Infection on Human Health	97
4.1.2	RSV Transmission	98
4.1.3	The Current Therapeutic Options and Opportunity for the Development of Treatments for RSV Infection	98
4.1.4	The Unique Challenge of RSV Vaccine Development	99
4.1.5	The Virus and the Replication Cycle	99
4.1.6	The Nucleoprotein–RNA Complex	100
4.1.7	The L Polymerase Protein	101
4.1.8	The P Phosphoprotein	101
4.1.9	The M2-1 Protein	102
4.1.10	The RSV-G Glycoprotein	102
4.1.11	The RSV-F Fusion Glycoprotein	102

4.1.12	The RSV-SH Glycoprotein	104
4.1.13	Antigenic Variation of RSV Surface Glycoproteins	108
4.1.14	Adaptation of RSV in the Community by Emergent High Titer Clades	108
4.2	RSV Longevity, Immune Evasion, and the Role of IgA	108
4.2.1	Evasion or Suppression of Immune Memory	108
4.3	The Impact of Immunoprophylaxis on the Health Burden of Respiratory Syncytial Virus	110
4.4	Distinct RSV Symptoms	110
4.4.1	Wheeze	110
4.4.2	The Effect of Immunoprophylaxis on the Development of Asthma	111
4.4.3	Epidemiology and Clinical Aspects of Adult RSV Disease	111
4.5	History of RSV and Vaccine Development	112
4.5.1	The Tragic History of RSV Vaccine Development in the First Failed RSV Vaccine Trials of the 1960s	112
4.6	New Developments in RSV Vaccine Development	113
4.6.1	Conformational Breathing of RSV-F Affects Neutralization Sensitivity	113
4.6.2	Measles Versus RSV Vaccine Development	113
4.6.3	The Lack of Immunogenicity, Immune Evasion, or Immune Suppression	114
4.6.4	Recent RSV Vaccines	114
4.6.4.1	Success in Secondary Endpoints	114
4.6.5	A Resurgence in Attenuated Replication-Competent Vaccines	114
4.6.5.1	Mechanisms of Protection from RSV that Require Attention in Vaccine Development	115
4.7	Antivirals and Therapeutic Antibodies	115
4.7.1	Immunoprophylaxis	115
4.7.2	RSV-IGIV	115
4.7.3	Palivizumab	116
4.8	Therapeutics for Treating Active RSV Infections	116
4.8.1	Immunotherapy under Clinical Development	117
4.9	Drug Targets	118
4.9.1	Novel Antivirals Undergoing Clinical Development	118
4.9.2	Other Investigational Treatments and Broad-Spectrum Antivirals	119
4.10	Conclusions	120
	References	120
<b>5</b>	<b>Herpes Simplex Viruses</b>	<b>133</b>
	<i>Alexander Birkmann</i>	
5.1	Introduction	133
5.2	Overview of the Viral Replication Cycle	134
5.3	Treatment of HSV Infections	135
5.4	Approved Anti-HSV Drugs	136
5.4.1	5-Substituted 2-Deoxyuridine Analogues	136
5.4.2	Vidarabine	137
5.4.3	Acyclic Guanosine Analogues	137
5.4.4	Foscarnet	139

- 5.4.5 Docosanol 139
- 5.5 Anti-HSV Drugs in Advanced Development or Recently Entering the Market 140
  - 5.5.1 Helicase–Primase Inhibitors 140
  - 5.5.2 Monoclonal Antibodies 141
  - 5.5.3 Therapeutic Vaccines 141
  - 5.5.4 Immunomodulators 142
- 5.6 HSV Resistance to Antiviral Drugs 142
  - 5.6.1 Epidemiology and Manifestation 142
  - 5.6.2 Resistance Mechanisms 143
  - 5.6.3 Management of Resistant HSV 143
- 5.7 HSV and Alzheimer’s Disease 144
- 5.8 Conclusion 144
- References 144

**6 Antiviral Strategies Against the Human Cytomegalo Virus Inhibitors of Viral Terminase 151**

*Helga Rübsamen-Schaeff*

- 6.1 The Need for Novel Drugs against CMV and Attempts of the Past 151
- 6.2 The Strategy for the Discovery of Letemovir 154
- 6.3 The Link between Preclinical Models and Clinical Efficacy 156
- 6.4 Clinical Experience 159
  - 6.4.1 Resistance Mutations and Resistance Development 164
  - 6.4.2 Resistance Observed in Clinical Studies 165
- 6.5 Other Potential Indications for Letemovir 167
- 6.6 Conclusions 169
- References 170

**7 Antiviral Targeting of the Complex Epstein Barr Virus Life Cycle 175**

*Christian Münz*

- 7.1 Disease Overview 175
- 7.2 Antiviral Strategies 177
  - 7.2.1 Pharmacological Inhibition 177
  - 7.2.2 B Cell Depleting Therapy 179
  - 7.2.3 Adoptive T Cell Transfer and Immune Checkpoint Blockade 180
  - 7.2.4 Vaccination 181
- 7.3 Open Issues 182
- Acknowledgements 183
- References 183

**8 Kaposi’s Sarcoma-associated Herpesvirus—Antiviral Treatment 191**

*Thomas F. Schulz*

- 8.1 Introduction to Kaposi’s Sarcoma-associated Herpesvirus (KSHV) 191
- 8.2 Epidemiological Considerations 191

8.3	Disease Overview	192
8.3.1	Kaposi's Sarcoma	192
8.3.2	Primary Effusion Lymphoma (PEL)	194
8.3.3	Multicentric Castleman's Disease (MCD)	194
8.3.4	KSHV and Polyclonal Post-transplant Lymphoproliferative Disease	195
8.3.5	Kaposi Sarcoma Herpesvirus-Associated Inflammatory Cytokine Syndrome (KICS)	195
8.3.6	KSHV and Hemophagocytosis, Bone Marrow Failure, and Hepatitis	196
8.4	Antiviral Strategies	196
8.4.1	Established Antiviral Strategies	196
8.4.1.1	Inhibitors of the KSHV DNA Polymerase	196
8.4.1.1.1	Activity in Tissue Culture	196
8.4.1.1.2	Activity in KSHV-infected Patients	199
8.4.1.1.3	Treatment of Kaposi Sarcoma	200
8.4.1.1.4	Treatment of PEL	200
8.4.1.1.5	Treatment of MCD	201
8.4.2	Kinase Inhibitors Against KSHV-associated Disease	201
8.4.2.1	Clinical Experience	201
8.4.2.2	Preclinical Studies	201
8.4.3	Other Established and Experimental Therapies Targeting KSHV-infected Cells	206
8.4.3.1	Interfering with Cellular Cytokines—Clinical Experience	206
8.4.3.2	Preclinical Data on Other Cellular Targets	207
8.5	New Antiviral Strategies Against KSHV in Preclinical Development	208
8.5.1	New Approaches to Target Productive (Lytic) KSHV DNA Replication and/or Packaging	209
8.5.2	Targeting KSHV Capsid Assembly	209
8.5.3	Targeted Immunotoxins	210
8.5.4	Targeting the Latency Phase of the KSHV Life Cycle	210
8.5.4.1	LANA (Latency-associated Nuclear Antigen)	211
8.5.4.2	vFLIP (Viral FLICE-inhibitory Protein)	212
8.5.4.2.1	Outlook	212
	References	213
<b>9</b>	<b>Direct-Acting Antivirals for the Treatment of Chronic Hepatitis B Virus (HBV) Infection</b>	<b>229</b>
	<i>Angelica Corcuera, Alastair Donald, and Andreas Urban</i>	
9.1	Nucleos(t)ide Analog Reverse Transcriptase Inhibitors	229
9.2	HBV Entry Inhibitors	232
9.3	HBV Capsid Assembly Modulators (CAMs)	232
9.3.1	HBV Core Protein	232
9.3.2	First-Generation CAMs	234
9.3.3	Recent Progress in Novel CAMs	236
9.3.4	Modes of Action of CAMs	237

- 9.3.5 Resistance Profile of CAMs 238
- 9.3.6 CAMs in Clinical Trials 242
- 9.4 Concluding Remarks 244
- References 244

**10 Hepatitis E Virus – Current Developments in Antiviral Strategies 253**

*Daniel Todt, Patrick Behrendt, and Eike Steinmann*

- 10.1 Introduction 253
- 10.2 Genetic Diversity and Molecular Virology of HEV 254
- 10.3 Clinical Course of HEV Infections 256
- 10.4 HEV Therapy 258
- 10.5 Development of Novel Antivirals Against HEV 259
- 10.6 Prevention of Infection and Vaccination Strategies 264
- 10.7 Conclusions 265
- References 266

**11 Antiviral Therapy of Adenovirus Infections 277**

*Peter Lischka*

- 11.1 Human Adenovirus 277
- 11.2 Adenovirus in Human Stem Cell Transplantation 279
  - 11.2.1 Incidence, Transmission, and Clinical Manifestation 279
  - 11.2.2 Current Therapy Strategies and Antiviral Agents 281
    - 11.2.2.1 Ribavirin 282
    - 11.2.2.2 (Val)Ganciclovir 282
    - 11.2.2.3 Cidofovir 283
  - 11.2.3 Novel Antiviral Approaches in Clinical Development 283
    - 11.2.3.1 Brincidofovir 283
- 11.3 Ocular Adenovirus Infections 285
  - 11.3.1 Incidence, Transmission, and Clinical Manifestation 285
  - 11.3.2 Current Therapy Strategies and Antiviral Agents 286
    - 11.3.2.1 Corticosteroids 286
    - 11.3.2.2 Povidone-iodine and SHP640 287
    - 11.3.2.3 Nucleoside Analogues 287
    - 11.3.2.4 Palliative Treatment 288
  - 11.3.3 Novel Antiviral Approaches in Clinical Development 288
    - 11.3.3.1 OKG-0301 288
    - 11.3.3.2 iVIEW-1201 288
- 11.4 Drug Targets for Direct Acting Antivirals 289
  - 11.4.1 Virus Attachment and Entry 289
  - 11.4.2 Virus Genome Replication 290
  - 11.4.3 Particle Maturation 290
- 11.5 Conclusion 291
- References 291

<b>12</b>	<b>ssDNA-Viruses: Human Parvovirus Infection</b>	<b>297</b>
	<i>Susanne Modrow</i>	
12.1	Introduction	297
12.2	Classification	297
12.3	Molecular Biology	298
12.4	Parvovirus Replication	300
12.5	Diseases Associated with Parvovirus Infection	301
12.5.1	Parvovirus B19	301
12.5.2	HBoV	302
12.6	Antiviral Chemotherapy of Parvovirus B19-infection	303
12.7	Therapeutic Options and Recommendations	303
12.7.1	Acute B19V-infection Associated with Transient Aplastic Crisis (TAC)	303
12.7.2	Prolonged B19V-symptoms in Immunocompetents	304
12.7.3	Fetal Disease	304
12.7.4	Immunocompromised Patients	304
	References	304
<b>13</b>	<b>Antiviral Targets and Strategies to Treat and Prevent Human Norovirus Infections</b>	<b>313</b>
	<i>Jana Van Dycke, Arno Cuvry, Johan Neyts, and Joana Rocha-Pereira</i>	
13.1	Introduction	313
13.1.1	Disease Burden and Pathogenesis	313
13.1.2	Viral Genome	315
13.1.3	Replication Cycle	315
13.1.4	<i>In Vitro</i> Models	316
13.1.5	<i>In Vivo</i> Models	317
13.1.5.1	Human Norovirus	317
13.1.5.2	The Murine Norovirus as a Surrogate for <i>In Vivo</i> Studies	318
13.2	Antiviral Targets	318
13.2.1	Binding and Entry	318
13.2.2	Nonstructural Proteins	320
13.2.2.1	NS1/2 (p48)	320
13.2.2.2	NS3 (NTPase/Helicase)	320
13.2.2.3	NS4 (p22)	321
13.2.2.4	NS5 (VPg)	321
13.2.2.5	NS6 (Protease)	322
13.2.2.6	NS7 (RNA-Dependent RNA Polymerase)	322
13.2.3	Host Factors	325
13.2.4	Antibodies	328
13.2.5	Gut Microbiota	328
13.2.6	Unknown Targets	330
13.3	Vaccine Development	331
13.4	Conclusion and Perspectives	332
	References	332

<b>14</b>	<b>Antiviral Strategies Against (Non-polio) Picornaviruses</b>	<b>347</b>
	<i>Rana Abdelnabi, Jim Baggen, Carmen Mirabelli, and Johan Neyts</i>	
14.1	Classification and Clinical Impact	347
14.2	The Enterovirus Replication Cycle	347
14.2.1	Virion Structure	347
14.2.2	Genome Structure	348
14.2.3	Replication Cycle Stages	349
14.2.3.1	Entry	349
14.2.3.2	Translation and Replication	350
14.2.3.3	Assembly and Release	350
14.3	Prevention	351
14.4	Antiviral Strategies Against Enteroviruses	352
14.4.1	Directly Acting Antivirals	352
14.4.1.1	Early-Stage Inhibitors	352
14.4.1.2	Viral Protease Inhibitors	355
14.4.1.3	2C Targeting Molecules	356
14.4.1.4	RNA-dependent RNA Polymerase (RdRp) “(3D) Inhibitors”	356
14.4.2	Host-targeting Antivirals	357
14.4.2.1	Inhibitors of Lipid Processing	357
14.4.2.2	Assembly Inhibitors	357
14.4.3	Monoclonal Antibodies	358
14.4.4	Alternative Strategies	358
14.4.4.1	Direct Targeting of the RNA Genome	358
14.4.4.2	Dual Target Therapeutics	358
14.5	Conclusions	359
	References	359
<b>15</b>	<b>Novel Antiviral Strategies Against Emerging Arbovirus Infections</b>	<b>367</b>
	<i>Yannick Brüggemann, Carina Elsner, and Stephanie Pfaender</i>	
15.1	Introduction	367
15.1.1	Zika Virus	368
15.1.2	Yellow Fever Virus	368
15.1.2.1	Dengue Virus	369
15.1.3	West Nile Virus	369
15.1.4	Chikungunya Virus	370
15.2	Intervention Strategies	371
15.3	Genome Organization and Viral Replication Cycle	371
15.4	Targets For Antiviral Therapy	374
15.5	Direct-acting Antivirals (DAAs)	374
15.6	RNA-dependent RNA Polymerase Inhibitors	374
15.7	Protease/Helicase Inhibitors	377
15.8	Envelope Protein Inhibitors	378
15.9	Capsid Protein Inhibitors	379
15.10	NS4B Inhibitors	379
15.11	Methyltransferase Inhibitors	379
15.12	Inhibitors with Nonspecific Action	380

15.13	Host Targeting Antivirals	380
15.14	Host Cell Nucleoside Biosynthesis Inhibitors	381
15.15	Host Cell Lipid Biosynthesis Inhibitors	382
15.16	Host Kinase Inhibitors	384
15.17	Protein Metabolism Inhibitors	385
15.18	Endocytosis and Membrane Fusion Inhibitors	387
15.19	Conclusion and Future Perspectives	387
	References	390
<b>16</b>	<b>Current Therapies for Biosafety Level 4 Pathogens</b>	<b>409</b>
	<i>Lucie Fénéant, Bianca Bodmer, Thomas C. Mettenleiter, Allison Groseth, and Thomas Hoenen</i>	
16.1	Introduction	409
16.2	Filoviruses	410
16.2.1	Virus and Disease Overview	410
16.2.2	Antiviral Strategies	411
16.2.2.1	Immunotherapies	411
16.2.2.2	Postexposure Prophylaxis	412
16.2.2.3	Small Molecules	413
16.2.2.4	Antisense Therapy	418
16.2.2.5	Host-directed Therapies	418
16.3	Henipaviruses	418
16.3.1	Disease Overview	419
16.3.2	Antiviral Strategies	419
16.3.2.1	Small Molecules	419
16.3.2.2	Immunotherapies	420
16.4	Arenaviruses	420
16.4.1	Old World Arenaviruses	420
16.4.1.1	Disease Overview	423
16.4.1.2	Antiviral Strategies	423
16.4.1.2.1	Small Molecules	423
16.4.1.2.2	Immunotherapies	425
16.4.2	New World Arenaviruses	426
16.4.2.1	Disease Overview	426
16.4.2.2	Antiviral Strategies	427
16.4.2.2.1	Immunotherapies	427
16.4.2.2.2	Small Molecules	428
16.5	Bunyaviruses	429
16.5.1	Disease Overview	429
16.5.2	Antiviral Strategies	430
16.5.2.1	Immunotherapies	430
16.5.2.2	Small Molecules	430
16.6	Considerations for the Development of Treatment Strategies Against Viral Hemorrhagic Fever Viruses	433
	References	435

<b>17</b>	<b>A Focus on Severe Acute Respiratory Syndrome (SARS) Coronavirus (SARS-CoVs) 1 and 2</b>	<b>449</b>
	<i>Rolando Cannalire, Enzo Tramontano, and Vincenzo Summa</i>	
17.1	Overview on Coronavirus (CoV)	449
17.1.1	CoV Epidemiology	449
17.1.2	HCoV Replication	450
17.1.3	Human Corona Virus (HCoV) Diseases Natural History	453
17.2	Licensed and Clinical Investigational Drugs Against CoVs	454
17.2.1	Licensed Drugs Against CoVs	455
17.2.2	Clinical Investigational Drugs Against CoVs	456
17.3	Medicinal Chemistry Approaches Toward the Identification of New Drugs	459
17.3.1	SARS-CoVs RdRp: Structure, Function, and Inhibition	460
17.3.2	The CoVs 3CL <sup>pro</sup> (or Main Protease): Structure, Function, and Inhibitors	463
17.3.3	The S Protein: Structure, Function, and Inhibition	472
17.4	Conclusions	477
	References	478
	<b>Index</b>	<b>487</b>